RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Clinical trials for RELAPSED OR REFRACTORY MULTIPLE MYELOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED OR REFRACTORY MULTIPLE MYELOMA trials appear
Sign up with your email to follow new studies for RELAPSED OR REFRACTORY MULTIPLE MYELOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New Triple-Action antibody enters human trials for Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase study tests an experimental drug called JNJ-79635322, a trispecific antibody designed to attack cancer cells in people with relapsed or refractory multiple myeloma or AL amyloidosis. About 180 participants will receive the drug to find the safest dose and check f…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
MRNA therapy takes on Hard-to-Treat blood cancer
Disease control Recruiting nowThis study tests a new mRNA medicine called mRNA-2808 in people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if it is safe and helps control the cancer. About 166 adults will take part in this early-phase trial.
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1, PHASE2 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated May 26, 2026 05:06 UTC
-
New Tri-Specific antibody takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-phase trial tests a new drug called SIM0500 in 130 adults with multiple myeloma that has come back or stopped responding to standard treatments. The drug is designed to help the immune system attack cancer cells from three different angles. The main goals are to check …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 05:02 UTC
-
New hope for Tough-to-Treat myeloma? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug, JNJ-87562761, in people with multiple myeloma whose cancer has returned or stopped responding to prior treatments. The main goals are to find a safe dose and check for side effects. About 80 participants will take part in this first-in-hum…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated May 26, 2026 05:00 UTC
-
New drug YKST02 takes on Hard-to-Treat multiple myeloma in early trial
Disease control Recruiting nowThis early-stage study tests a new medicine, YKST02, in about 70 people whose multiple myeloma has returned or not responded to at least two prior treatments. The main goals are to check the drug's safety and find the right dose, while also looking for signs that it can control t…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Excyte Biopharma Ltd • Aim: Disease control
Last updated May 26, 2026 04:59 UTC
-
New drug combo targets Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis early-stage trial is testing a combination of two experimental drugs, cevostamab and elranatamab, in people with multiple myeloma that has returned or stopped responding to prior therapies. The main goals are to check the safety of the combination and find the best dose for …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated May 26, 2026 04:37 UTC
-
New Dual-Target CAR t therapy takes on Hard-to-Treat myeloma
Disease control Recruiting nowThis early-stage study tests a new treatment called O&D-001 for people with multiple myeloma that has come back or not responded to other therapies. The treatment uses specially engineered immune cells (CAR T cells) that target two proteins, BCMA and GPRC5D, on myeloma cells. The…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE1 • Sponsor: O&D BioTech Group CO., Limited • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for myeloma: experimental drug QLS32015 faces off against standard care
Disease control Recruiting nowThis study tests a new drug called QLS32015 against two standard treatments (pomalidomide with dexamethasone, or selinexor with dexamethasone) in people whose multiple myeloma has returned or stopped responding to prior therapy. About 228 adults aged 18 and older will be randomly…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New drug combo aims to control Hard-to-Treat multiple myeloma
Disease control Recruiting nowThis study tests a new drug called F182112 given with different treatment plans for people whose multiple myeloma has come back or stopped responding to prior therapies. About 90 participants will receive the drug combination to see if it can shrink tumors and delay cancer growth…
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Shandong New Time Pharmaceutical Co., LTD • Aim: Disease control
Last updated May 26, 2026 04:35 UTC
-
New hope for Hard-to-Treat myeloma: drug cocktail trial launches
Disease control Recruiting nowThis study tests several combinations of the experimental drug QLS32015 with other medicines in 160 people whose multiple myeloma has returned or not responded to prior treatment. The goal is to see if these combos can shrink tumors or make cancer undetectable. Participants will …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE2 • Sponsor: Qilu Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 22, 2026 13:52 UTC
-
New hope for myeloma: experimental combo faces off against standard care
Disease control Recruiting nowThis study compares a new drug combination (mezigdomide, bortezomib, and dexamethasone) against a standard combination (pomalidomide, bortezomib, and dexamethasone) in about 810 adults with multiple myeloma that has come back or stopped responding to treatment. Participants must …
Matched conditions: RELAPSED OR REFRACTORY MULTIPLE MYELOMA
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated May 20, 2026 11:56 UTC